ArticleSkin health and disease2026

Guselkumab treatment of psoriasis results in sustained reduction of systemic inflammatory biomarkers to week 48 in three phase III randomized controlled trials.

Niamh Kearney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.